GSK confirmed this morning that the disappointing readout from the DREAMM-3 trial of multiple myeloma therapy Blenrep reported earlier this month means that it will take the drug off the US market.

GSK has claimed its second breakthrough designation from the FDA for antibody-drug conjugate GSK5764227, which it licensed from China's Hansoh Pharma in a $1.7 billion deal. The status has been ...

Involves transaction of at least 0.5% of the listed shares of a company. What was Glaxosmithkline Pharmaceuticals Ltd share price previously? Glaxosmithkline Pharmaceuticals Ltd share price was up ...

Thank you for reporting this station. We will review the data in question. You are about to report this weather station for bad data. Please select the information that is incorrect.

Thank you for reporting this station. We will review the data in question. You are about to report this weather station for bad data. Please select the information that is incorrect.

Copyright © 2025 MarketWatch, Inc. All rights reserved.

They consider it highly unlikely the Fed would not honour its funding backstops, but have held informal discussions about this possibility because their trust in the U.S. government has been ...

Vageshwari Properties has purchased a historic bungalow at Malabar Hill in Mumbai for Rs 276 crore. The property, known as Laxmi Nivas, was a secret hideout for freedom fighters during the Quit... Mar ...

3 Year 85.66% 86.14% 34.23% 36.41% ...